Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My Questrade account tells me the P/E is 0.05
Not a problem.
The $400,000 figure is off of Japan alone. Not including North American or European sales,
Interview with Dr. Chris Otiko from October 5, 2017.
It gives you an update on the outlook of Viaderma Inc moving into 2018 and beyond.
https://upticknewswire.com/interview-ceo-dr-chris-otiko-of-viaderma-inc-otcpink-vdrm/
DD Information!
Why hasn't the new PR been stickied or posted to the Viaderma Inc. IHUB page?
It’s been long enough, PLEASE UPDATE!
ViaDerma, Inc. Commences Distribution of VitaStem(TM), its FDA Registered Topical Antibiotic, and Looks to Expand its Partnership with Biogenx
Oct 19, 2017
OTC Disclosure & News Service
-
ViaDerma, Inc. Commences Distribution of VitaStem(TM), its FDA Registered Topical Antibiotic, and Looks to Expand its Partnership with Biogenx
ViaDerma's Manufacturer has completed the first run of its topical antibiotic being sold as VitaStem by its Sales, Marketing and Distribution Partner Biogenx, Inc.; Distribution will begin as the product is shipped to Distribution points in Florida and Abroad
LOS ANGELES, CA--(Marketwired - October 19, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has begun distribution of its highly anticipated topical antibiotic ointment. Its marketing, sales and distribution partner, Biogenx, Inc. has been preselling the product, under the name of VitaStemâ„¢, which retails for $99 and can be purchased online at www.Biogenx.net. The Company's manufacturing partner has completed the first production run of 15,000 units of the product overcoming several manufacturing delays. The Company expects to ramp up production on a monthly basis and the first orders shipped out yesterday. Since the promising results of clinical studies of VitaStem in hospital groups in Japan and the Philippines, the Company will send a portion of the first run to Japan and the Philippines. The Distributors are also interested in ViaDerma's several follow-on products, using ViaDerma's proprietary solution, which the Company is expecting additional FDA registration numbers throughout the rest of 2017.
The Company's President, Dr. Christopher Otiko said, "Now that the product delays are over and we are in the distribution phase we expect the orders to come in from several key countries abroad. The quick response by customers in our marketing studies has shown positive results and this has led to an increased interest in our products due to the need in several markets around the world. This should open the door for future products in several key markets. Our contract manufacturer has the capabilities to manufacture most of our products and we look forward to building a lasting relationship to deliver high quality pharmaceuticals to our distributors."
About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's products use an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD's and THC with the delivery system was filed in 2017. The use of CBD's is for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Crohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit: www.viadermalicensing.com
Forward Looking Statements
Forward-Looking Statements certain statements in this release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified using words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors. We assume no obligation to update the information contained in this news release.
Contact information:
Investor Relations
Email: info@viadermalicensing.com
Phone: 310-734-6111
Copyright © 2017 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Yes.
https://www.pacermonitor.com/public/case/21120838/Keough_v_Otiko_et_al
4th quarter will make shareholders giddy as school girls!
VDRM Long!!
I'm just being realistic.
I know Viaderma Inc. will be huge soon!
VDRM long!!
Correct.
Not trying to be a downer, but realistically cut that in half for wholesale price.
VDRM long!!
Your right!
In business you have to take the good with the bad. Sometimes people are not able to overcome it and sometimes Yazbeck does act out.
I have noticed that he has grown into his role at MYDX over the years and that that past few moves show that he is getting more comfortable and stronger.
This only help MYDX.
MYDX Long!!
I have no problem with him being the Bully because that keeps the coffers full and in return makes the company stronger to adequately bring out the related products.
MYDX Long!!!
Re: New Sec Filing
On April 30, 2017, the Company sent an initial payoff request to Crown so that it could repay the amount due pursuant to the Note (including all penalties and interest) prior to the Prepayment Deadline. Subsequently, between May 9 th and June 4 th , the Company sent further requests for such wire instructions. Despite such requests, on July 3, 2017, Crown converted $36,749.04 (the entire amount due pursuant to the Note including all penalties and interest) into 14,699,616 shares of the Company’s common stock. In light of the Company’s notification required in the SPA to repay the Note pursuant to its terms, the Company believes Crown may have breached the terms of the Note.
Could the new Sec Filing be related to a Crown bridge settlement??
Instead of going after damages, MYDX could have gone to arbitration and asked for the shares plus interest during that time period.
If this is accurate then it shows that MYDX won't lie down and be bullied.
MYDX Long!!
Have the people who ordered Vitastem received their orders yet?
Calm down everyone!!
We all want Viaderma Inc to do well and what they promised.
According to my count from August 18/17 they said 30-45 days. I'm counting business days and 45 days would bring it to October 20/17. Just because a PR doesn't come out on that day, I won't jump to conclusions.
Everyone has invested their hard earned money and they don't want to lose. We held out this long another few weeks is not going to hurt now.
VDRM Long!
Stay strong VDRM shareholders.
Believe me I know it's hard to keep believing in this company since the share price keeps dropping. The 2nd quarter report will be good for this company.
Remember FDA has approved viabecline and prolayed for Viaderma Inc. Read this article below and you may find solace in it.
https://claytonnewsreview.com/needle-tilting-mid-session-for-viaderma-inc-vdrm/123727/
Long on VDRM!!
Is that true Pstats?
The lawsuit has been dismissed against Otiko and Viaderma Inc?
VDRM Long!!!
Interesting!
That a little too much!
How would we do that?
I'm tired of these ticks too!
Interesting article, I think true Viaderma Inc shareholders will find this helps when the ticks (MM's) are manipulating the share price.
http://finnewsreview.com/unusual-activity-spotted-in-viaderma-inc-vdrm/
They will not be able to hold Viaderma Inc down much longer. I know it's hard but we have to stick it out until the share price represents the true value of the company.
The profits and sales from Viabecline overseas alone will right this ship and put us pointing up to the sky within 30 days.
2nd quarter report will prove what we all believe in Viaderma Inc.
I can see what the MM's are trying to do.
Just because there is a bid that low, means that the long term shareholders of VDRM have to stay strong and oppose these ticks bleeding the share price.
Casinoo,
Your chart says what you want to say, my chart says what Viaderma will do!
https://www.tradingview.com/chart/VDRM/7es1horS-Great-news-today-I-believe-we-see-the-start-of-a-bull-trend/
Thank you MegaVerde.
Any other future articles would help and show the MM's that the shareholders are united!
Thank you.
Stay strong, Viaderma will prevail!
Thank you for your reply Bartletpear.
I'm truly disgusted that the MM's think they can make money off the backs of the shareholders. We must stand strong and unite so that we can truly savour our victory once the MM's can't manipulate the stock price.
I'm in no way a wealthy person but my hard earned money is in Viaderma Inc which will survive these MM's manipulation, fraudulent lawsuit and FDA approval of the sexual health cream.
We must stand strong now for a future high value share price.
I'm long on Viaderma holding 2 million shares.
How do we hurt the MM's for their blatant sabotage of a company that has a bright future and has robbed shareholders of share price?
I'm not selling because I believe in Viaderma Inc but I know there are a few shareholders who can't keep up with losing share price on their investment for various reasons. How can we help them stay strong?
Any advice?
Interesting!!
I just want to state I'm long on MYDX, I truly believe in the technology and company as a whole.
I've been frustrated in how the stock has been manipulated over the past month or so by outside influences trying to erode the value of MYDX.
This link shows that the company is truly undervalued and some type of manipulation is being conducted.
I believe that once the 1st quarter financials come out this stock will blossom and that these outside influencers will not be able to control it anymore.
ozarktimes.com/unusual-activity-spotted-in-mydx-inc-mydx/29251/
Correct, we truly don't know why the testing is being done now except for our own assumptions.
We both believe in Viaderma Inc. and their products. Once the testing is completed and results provided, others will jump on board.
The share price will be rewarded for the investors that were there and completed their own due diligence.
"The Company is in the final testing phase before manufacturing its Patent Pending (provisional patent number 62433964) topical antibiotic product, Viabecline. FDA registered Viabecline directly targets the affected area of the body by applying the medication onto the skin in an ointment based topical solution. Viabecline is registered with the FDA (NDC number 69006-002-00) as a first aid to treat cuts, scrapes and burns."
I completely understand your hesitation as I feel completely the same.
From my understanding the diabetic foot cream was registered with the FDA as a first aid medication previously. Since the patent was abandoned and has been re registered as a diabetic foot cream, independent tests need to be completed for the purpose of sales in the USA.
This hasn't stopped production or sales in other parts of the world as they mentioned would be targeted before entering the USA.
The independent testing being completed now, is outside the realm and control of Viaderma Inc. Which means any information good or bad will be available wide spread for everyone.
I believe the steps Viaderma Inc. has taken is slow but their process for releasing their products is done in line with a lot of major pharmaceutical companies.
"In addition to that, initial production for Viabecline, our topical antibiotic ointment is on track, and we have started a new independent study in Texas to prove Viabecline's efficacy in treating diabetic foot wounds."
You must remember the previous data that was completed was in house.
This will be a complete study to quantify the said data independently. As a investor this is what I want to see completed to prove the results were independently verified instead of just drinking the kool aid!